The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity ...
Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an ...
Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...
While some analysts expect the 2025 IPO market to be relatively cool in the near-term, others anticipate more bids than in ...
Sionna Therapeutics (SION), which is developing drugs to treat cystic fibrosis, has filed to raise $100M through an initial public offering. While Sionna (SION) didn't disclose terms in its SEC filing ...
Formed in 2019, Sionna's most recent financing was a $182 million third round that closed last year, which followed a $111 ...
A Waltham biotech focused on cystic fibrosis and a Boston biotech led by serial founder Gary Glick are the first ...
Sionna Therapeutics and Odyssey Therapeutics join Metsera and Maze in filing for IPOs, with Sionna focused on cystic fibrosis ...
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
Sionna Therapeutics is working on therapies for cystic fibrosis, several of which are in early-stage testing. Odyssey Therapeutics aims to tap Wall Street to develop targeted drugs for immune ...